Prostate cancer
Prostate cancer begins as uncontrolled growth of cells within the prostate gland, a small organ situated below the bladder in the male reproductive system. Most tumors originate in the peripheral zone, the outermost layer of this gland. As these cells multiply, they form clusters known as prostatic intraepithelial neoplasia or PIN. Some PINs evolve into full tumors by accumulating large-scale genetic mutations that rearrange chromosome sequences. A common alteration involves gene fusion between TMPRSS2 and the oncogene ERG, found in up to 60% of all prostate tumors. Other frequent changes include disabling mutations in the SPOP gene affecting 15% of cases, or hyperactivation of FOXA1 seen in 5%. These genetic errors allow cells to replicate abnormally while evading normal death signals. As the tumor grows, it stimulates new blood vessel formation to support its expansion. Eventually, cells detach from their original site and travel through lymphatic systems to nearby nodes or enter the bloodstream to reach bone marrow. Metastases disrupt normal body function and cause most discomfort associated with advanced disease.
Most prostate cancers are detected through screening tests before symptoms appear. Blood tests measure levels of prostate-specific antigen or PSA, a protein elevated in men with enlarged prostates whether due to cancer or benign conditions. The typical man has around 1 nanogram of PSA per milliliter of blood. Levels below this average suggest very low risk for dangerous cancer over the next decade. Men with PSA above 4ng/mL face increased risk, with one in four developing prostate cancer. Those exceeding 10ng/mL have even higher odds, as more than half develop the disease. Doctors often repeat these tests weeks later since levels fluctuate due to infection or recent ejaculation. A digital rectal exam follows where a physician inserts a lubricated finger into the rectum to feel for stiff lumps against the gland. Tumors feel irregular compared to healthy tissue, though hardening can also stem from non-cancerous enlargement. Only about 20 to 25% of abnormal findings on exams confirm actual cancer. Definitive diagnosis requires biopsy samples taken via needle passing through the rectum guided by ultrasound or MRI. Pathologists examine these under microscopes to assign Gleason scores ranging from 3 to 10 based on how much tumor cells differ from normal tissue.
Men diagnosed with low-risk tumors often defer treatment and monitor progression through active surveillance programs. These involve testing every six months using PSA checks and annual digital exams alongside MRIs repeated every few years. At least half of men remain on surveillance without needing direct intervention. When therapy becomes necessary, options include radiation or surgical removal of the entire gland known as radical prostatectomy. Radiation delivery varies between intensity-modulated techniques allowing high doses above 80 Gy to target the prostate while sparing other organs, and brachytherapy involving permanent radioactive implants inserted directly into the gland during a single session. Surgery typically utilizes robotic tools in wealthier nations to make precise movements through small abdominal holes resulting in shorter hospital stays and less blood loss than traditional open approaches. Both treatments carry risks including erectile dysfunction and urinary incontinence depending on surgeon skill and patient age. After surgery PSA levels drop rapidly reaching undetectable states within two months whereas radiotherapy reduces them more slowly over two years. Rising PSA after either procedure signals recurrence prompting further radiation which cuts future progression risk by three-quarters.
Metastatic disease requires androgen deprivation therapy reducing male sex hormones that prostate cells need to survive. First-line drugs like leuprolide or goserelin block testosterone synthesis but cause brief initial rises potentially worsening symptoms before improvement occurs. Alternative agents such as degarelix lower levels immediately without this spike. Hormone therapy halts growth in over 95% of patients though side effects include hot flashes muscle loss bone density reduction fatigue depression and increased diabetes risk. Eventually tumors evolve resistance becoming castration-resistant prostate cancer characterized by rising PSA and new metastases despite low testosterone. Standard care combines chemotherapy docetaxel with antiandrogens like enzalutamide or abiraterone acetate blocking receptor signaling. Cell therapies remove immune cells treat them externally then re-inject to target cancer specifically. Radiopharmaceuticals bind PSMA proteins found on tumor surfaces destroying those cells directly. Genetic testing identifies mutations enabling PARP inhibitors like olaparib for DNA repair defects. Bone metastases present in 85% of cases cause severe pain treated with nonsteroidal anti-inflammatory drugs or external beam radiation shrinking nearby tumors. Radioactive compounds accumulate disproportionately in bone helping reduce size while systemic chemotherapies shrink tumors overall.
A prostate mass was first described in 1817 by English surgeon George Langstaff following autopsy of a man dying at 68 with urinary symptoms. John Adams provided the first confirmed cancer case in 1853 when he had pathologists examine a tumor from a patient suffering similar problems. Early reports found only 50 cases documented until surgical techniques improved understanding around the turn of the century. Perineal prostatectomy became standard practice starting in 1904 under Hugh H. Young at Johns Hopkins Hospital initially relieving urinary blockage rather than curing cancer. Transurethral resection replaced this method for symptom relief in 1931 before Terence Millin introduced retropubic approaches in 1945 improving access to pelvic lymph nodes. Patrick Walsh refined these procedures in 1983 preserving erectile function by avoiding nerve damage. Radiation therapy emerged gradually beginning with radium implants in urethra or rectum early twentieth century. External beam radiotherapy arrived in the 1950s enabling powerful machines to reach deeper targets. Charles Huggins demonstrated systemic hormone reduction effectiveness using surgical castration or estrogen in 1941 earning him the 1966 Nobel Prize. Andrzej Schally developed GnRH agonists later recognized with the 1977 Nobel Prize offering safer alternatives to estrogen. Chemotherapy trials failed initially until docetaxel approval
in 2004 marked first survival benefit for advanced stages.
Common questions
What is prostate cancer and where does it originate?
Prostate cancer begins as uncontrolled growth of cells within the prostate gland, a small organ situated below the bladder in the male reproductive system. Most tumors originate in the peripheral zone, which is the outermost layer of this gland.
How do doctors detect prostate cancer using PSA levels?
Blood tests measure levels of prostate-specific antigen or PSA to screen for the disease before symptoms appear. Men with PSA above 4ng/mL face increased risk, while those exceeding 10ng/mL have even higher odds as more than half develop the disease.
What are the treatment options for low-risk prostate cancer cases?
Men diagnosed with low-risk tumors often defer treatment and monitor progression through active surveillance programs involving testing every six months. When therapy becomes necessary, options include radiation or surgical removal of the entire gland known as radical prostatectomy.
How is metastatic prostate cancer treated with hormone therapy?
Metastatic disease requires androgen deprivation therapy reducing male sex hormones that prostate cells need to survive. First-line drugs like leuprolide or goserelin block testosterone synthesis but cause brief initial rises potentially worsening symptoms before improvement occurs.
When was the first case of prostate cancer documented by history?
A prostate mass was first described in 1817 by English surgeon George Langstaff following autopsy of a man dying at 68 with urinary symptoms. John Adams provided the first confirmed cancer case in 1853 when he had pathologists examine a tumor from a patient suffering similar problems.